Tissue Fusion to Stop Post-Hemodialysis Bleeding

Information

  • Research Project
  • 6791063
  • ApplicationId
    6791063
  • Core Project Number
    R43HL075978
  • Full Project Number
    1R43HL075978-01A1
  • Serial Number
    75978
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/8/2004 - 21 years ago
  • Project End Date
    3/7/2005 - 20 years ago
  • Program Officer Name
    MOXEY-MIMS, MARVA M.
  • Budget Start Date
    9/8/2004 - 21 years ago
  • Budget End Date
    3/7/2005 - 20 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/8/2004 - 21 years ago

Tissue Fusion to Stop Post-Hemodialysis Bleeding

[unreadable] DESCRIPTION (provided by applicant): [unreadable] Of the 400,000 Americans living with end stage renal disease, nearly 250,000 undergo hemodialysis treatments 2-3 times each week. The cost of establishing and maintaining vascular access in dialysis patients is a staggering $13,500 per patient per annum. The frequency of puncture often leads to complications, such as uncontrollable bleeding after dialysis needle removal, resulting in 70% of patients requiring two or more corrective surgical procedures annually to maintain access. To address the bleeding problem, Rocky Mountain Biosystems, Inc., is developing an activated adhesive technology called FastSeal, which is designed to produce a fluid-tight seal in needle tracts. FastSeal uses a focused, high-frequency magnetic field, to effect localized heating of a novel biocompatible adhesive thus affecting an immediate seal. The adhesive can be used in wet or dry environments, can predictably be used in the presence of pressures, and is very economical. The investigators propose to further develop the adhesive and applicator, and to test the FastSeal process in an in vitro skin puncture model. The focus of Phase II will be developing a clinical system for sealing the needle tract and the site of venous access, whether synthetic or vascular. [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99449
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:99449\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ROCKY MOUNTAIN BIOSYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    140454997
  • Organization City
    WHEAT RIDGE
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80033
  • Organization District
    UNITED STATES